Evidence map›Paper›PMID 41661445›Full record

ArticleJournal of endocrinological investigation2026

Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.

Carel W le Roux, Nicolae Done, Alan J M Brnabic, Abigail Zion, Ilya Lipkovich, Zbigniew Kadziola, Julia P Dunn, Urvi Desai, Noam Kirson, Georgios K Dimitriadis and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Carel W le RouxUniversity College Dublin, Conway Institute Belfield Dublin 4, Ireland and Ulster University, Cromore Road, Coleraine, Co., Londonderry, BT52 1SA, UK.
Nicolae DoneAnalysis Group, Inc, 111 Huntington Av, 14th Floor, Boston, MA, 02199-7668, USA.
Alan J M BrnabicEli Lilly and Company, Level 9, 60 Margaret St, Sydney, NSW, 2000, Australia. alan_brnabic@lilly.com.ORCID http://orcid.org/0000-0003-4303-2515
Abigail ZionAnalysis Group, Inc, 111 Huntington Av, 14th Floor, Boston, MA, 02199-7668, USA.
Ilya LipkovichEli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46285, USA.
Zbigniew KadziolaEli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46285, USA.
Julia P DunnEli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46285, USA.
Urvi DesaiAnalysis Group, Inc, 111 Huntington Av, 14th Floor, Boston, MA, 02199-7668, USA.
Noam KirsonAnalysis Group, Inc, 111 Huntington Av, 14th Floor, Boston, MA, 02199-7668, USA.
Georgios K DimitriadisEli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46285, USA.
Hong KanEli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46285, USA.

Funding

Eli Lilly and Company Eli Lilly and Company
6 · The paper itself

Abstract

purposeThe SURMOUNT-5 trial demonstrated greater weight reduction with tirzepatide vs. semaglutide in adults with obesity without diabetes. This study compared real-world weight reduction and cardiometabolic parameters associated with tirzepatide and semaglutide for obesity management.

methodsA retrospective cohort study was conducted using Truveta de-identified US electronic health record data. Adults with obesity or overweight and ≥ 1 obesity-related complication, without diabetes, who initiated tirzepatide or semaglutide December 2023–June 2024 and adhered to treatment, were followed for 6 months. Primary outcome was percentage weight change from baseline. Secondary outcomes included weight-reduction targets and changes in body mass index (BMI) and cardiometabolic parameters. Primary analysis employed propensity-score weighted regression. Sensitivity analyses included modified intention-to-treat.

resultsAmong 2,396 on-treatment patients (1,003 tirzepatide; 1,393 semaglutide), greater 6-month mean percentage weight reduction was observed with tirzepatide (–11.15% vs. −8.83%; adjusted difference −2.32%-points [95% CI: −3.17, −1.48]). Higher proportions of tirzepatide-treated patients achieved 5%, 10%, 15%, and 20% weight-reduction targets. Greater reductions in BMI, blood pressure, and haemoglobin A1c were observed with tirzepatide. More patients received higher doses of semaglutide (≥ 1.7 mg; 67.7%) vs. tirzepatide (≥ 10 mg; 42.4%). Sensitivity analysis findings were consistent.

conclusionsConsistent with clinical trials, real-world tirzepatide treatment was associated with greater 6-month weight reduction and more frequent achievement of weight-reduction targets and improvements in select cardiometabolic parameters than semaglutide among adults with obesity without diabetes. This early emergence of tirzepatide’s comparative advantage over semaglutide was observed despite more semaglutide-treated patients receiving higher doses than tirzepatide-treated patients.

Indexed as

Anti-Obesity AgentsGlucagon-Like PeptidesObesityTirzepatideAdultBody Mass IndexFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesSemaglutideTreatment OutcomeUnited StatesWeight LossAnti-Obesity AgentsGlucagon-Like PeptidesSemaglutideTirzepatideComparative effectivenessObesityReal-world evidenceSemaglutideTirzepatide

Identifiers

PMID41661445
PMCPMC12924827

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.